Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Intravenous Neridronic Acid in CRPS
NCT02972359Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of neridronic acid in complex regional pain syndrome (CRPS), sponsored by Grünenthal GmbH. Primary endpoint: Treatment Emergent Adverse Event. Started Dec 2016; status: completed.
02
Drugs
neridronic acid
03
Conditions
complex regional pain syndrome (CRPS)
Beyond the preview
Go deeper on NCT02972359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972359.